Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications

Trial Profile

A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTX A51 (Primary)
  • Indications Liposarcoma
  • Focus Adverse reactions

Most Recent Events

  • 28 Apr 2025 According to Edgewood Oncology media release, new preclinical efficacy data supporting this trial, from an Investigator-Sponsored preclinical Study of BTX-A51 in liposarcoma models, has been presented at the American Association of Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025, in Chicago. These data further support the ongoing clinical advancement of BTX-A51 in this investigator-sponsored Phase 1 pilot study.
  • 30 Aug 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Nov 2024 to 1 Sep 2024.
  • 30 Aug 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top